Literature DB >> 17934327

Axonal degeneration in motor neuron disease.

Lindsey R Fischer1, Jonathan D Glass.   

Abstract

Growing evidence from animal models and patients with amyotrophic lateral sclerosis (ALS) suggests that distal axonal degeneration begins very early in this disease, long before symptom onset and motor neuron death. The cause of axonal degeneration is unknown, and may involve local axonal damage, withdrawal of trophic support from a diseased cell body, or both. It is increasingly clear that axons are not passive extensions of their parent cell bodies, and may die by mechanisms independent of cell death. This is supported by studies in which protection of motor neurons in models of ALS did not significantly improve symptoms or prolong lifespan, likely due to a failure to protect axons. Here, we will review the evidence for early axonal degeneration in ALS, and discuss possible mechanisms by which it might occur, with a focus on oxidative stress. We contend that axonal degeneration may be a primary feature in the pathogenesis of motor neuron disease, and that preventing axonal degeneration represents an important therapeutic target that deserves increased attention. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934327     DOI: 10.1159/000107704

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  67 in total

1.  SOD1 targeted to the mitochondrial intermembrane space prevents motor neuropathy in the Sod1 knockout mouse.

Authors:  Lindsey R Fischer; Anissa Igoudjil; Jordi Magrané; Yingjie Li; Jason M Hansen; Giovanni Manfredi; Jonathan D Glass
Journal:  Brain       Date:  2010-11-14       Impact factor: 13.501

2.  The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth.

Authors:  Claudia Fallini; Gary J Bassell; Wilfried Rossoll
Journal:  Hum Mol Genet       Date:  2012-05-28       Impact factor: 6.150

Review 3.  Investigation of nerve injury through microfluidic devices.

Authors:  Rezina Siddique; Nitish Thakor
Journal:  J R Soc Interface       Date:  2013-11-13       Impact factor: 4.118

Review 4.  Axonal transport defects in neurodegenerative diseases.

Authors:  Gerardo A Morfini; Matthew Burns; Lester I Binder; Nicholas M Kanaan; Nichole LaPointe; Daryl A Bosco; Robert H Brown; Hannah Brown; Ashutosh Tiwari; Lawrence Hayward; Julia Edgar; Klaus-Armin Nave; James Garberrn; Yuka Atagi; Yuyu Song; Gustavo Pigino; Scott T Brady
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

5.  The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.

Authors:  Kow Essuman; Daniel W Summers; Yo Sasaki; Xianrong Mao; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Neuron       Date:  2017-03-22       Impact factor: 17.173

Review 6.  Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases.

Authors:  Junying Yuan; Palak Amin; Dimitry Ofengeim
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

7.  Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration.

Authors:  Albert L Misko; Yo Sasaki; Elizabeth Tuck; Jeffrey Milbrandt; Robert H Baloh
Journal:  J Neurosci       Date:  2012-03-21       Impact factor: 6.167

8.  An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient Autopsies.

Authors:  Grant Coan; Cassie S Mitchell
Journal:  Neurodegener Dis       Date:  2015-07-16       Impact factor: 2.977

9.  Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis.

Authors:  Emiliano Trias; Mariángeles Kovacs; Peter H King; Ying Si; Yuri Kwon; Valentina Varela; Sofía Ibarburu; Ivan C Moura; Olivier Hermine; Joseph S Beckman; Luis Barbeito
Journal:  Glia       Date:  2019-12-20       Impact factor: 7.452

10.  The androgen receptor's CAG/glutamine tract in mouse models of neurological disease and cancer.

Authors:  Andrew P Lieberman; Diane M Robins
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.